Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07854301). This is a study registration, not published results. Lead sponsor: State University of New York at Buffalo. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 100 participants (ESTIMATED). Conditions: Remote vs. In-Person, Remote Visits, In-person Visits. Interventions: BEHAVIORAL: mobile health application (Moodivate). Primary outcome measures: Accrual efficiency/Pre-treatment visits , ~1 month; Trial Quality: Retention , ~3 months; Trial Quality: Treatment utilization , ~3 months (assessed from T/A1 [when app is distributed] through T/A5); Trial quality: Biospecimen completion rates , ~3 months (assessed at T/A Visits 1,2, 3, 4, and 5). Brief summary: The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.